Ipilimumab/nivolumabImmune related myositis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1827卷 / 1期

关键词：

D O I：

10.1007/s40278-020-84940-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：185 / 185

相关论文

共 50 条

[21] Ipilimumab/nivolumabImmune mediated hepatitis: case report
Reactions Weekly, 2019, 1757 (1) : 176 - 176
[22] Ipilimumab/nivolumabImmune myocarditis: case report.
Reactions Weekly, 2020, 1802 (1) : 171 - 171
[23] NivolumabImmune-mediated myositis: case report
Reactions Weekly, 2020, 1834 (1) : 208 - 208
[24] Ipilimumab/nivolumabImmune mediated hepatitis: case report
Reactions Weekly, 2021, 1869 (1) : 193 - 193
[25] Ipilimumab/nivolumabImmune thrombocytopenia and hypothyroidism: case report
Reactions Weekly, 2022, 1926 (1) : 278 - 278
[26] Ipilimumab/NivolumabImmune checkpoint inhibitor-related diarrhoea and colitis: case report
Reactions Weekly, 2020, 1818 (1) : 153 - 153
[27] Ipilimumab/nivolumabImmune-mediated colitis: case report
Reactions Weekly, 2021, 1836 (1) : 437 - 437
[28] Ipilimumab/nivolumabImmune-mediated thyroiditis: case report
Reactions Weekly, 2023, 1957 (1) : 311 - 311
[29] Ipilimumab/nivolumabImmune-mediated meningoencephalitis: case report
Reactions Weekly, 2022, 1895 (1) : 231 - 231
[30] Ipilimumab/nivolumabImmune-mediated colitis : case report
Reactions Weekly, 2021, 1885 (1) : 281 - 281

← 1 2 3 4 5 →